Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin
Digital
- Autores:
-
Ferrannini, Giulia
Gerstein, Hertzel
Colhoun, Helen Martina
Dagenais, Gilles R.
Diaz, Rafael
Dyal, Leanne
Lakshmanan, Mark
Mellbin, Linda
Probstfield, Jeffrey
Riddle, Matthew Casey
Shaw, Jonathan Edward
Avezum, Alvaro
Basile, Jan Neil
Cushman, William C.
Jansky, Petr
Keltai, Mátyás
Lanas, Fernando
Leiter, Lawrence Alan
Lopez-Jaramillo, Patricio
Pais, Prem
Pīrāgs, Valdis
Pogosova, Nana
Raubenheimer, Peter Johann
Huey-Herng Sheu, Wayne
Rydén, Lars
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2021
- Institución:
- Universidad de Santander
- Repositorio:
- Repositorio Universidad de Santander
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.udes.edu.co:001/6070
- Acceso en línea:
- https://doi.org/10.1093/eurheartj/ehaa777
https://repositorio.udes.edu.co/handle/001/6070
- Palabra clave:
- Cardiovascular disease
GLP-1-based therapy
Metformin
Mortality
Morbidity
- Rights
- closedAccess
- License
- Copyright © The Authors, European Society of Cardiology, 2021
| id |
RUDES2_2455f42ea5e38089a1203234cab67e22 |
|---|---|
| oai_identifier_str |
oai:repositorio.udes.edu.co:001/6070 |
| network_acronym_str |
RUDES2 |
| network_name_str |
Repositorio Universidad de Santander |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin |
| title |
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin |
| spellingShingle |
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin Cardiovascular disease GLP-1-based therapy Metformin Mortality Morbidity |
| title_short |
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin |
| title_full |
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin |
| title_fullStr |
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin |
| title_full_unstemmed |
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin |
| title_sort |
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin |
| dc.creator.fl_str_mv |
Ferrannini, Giulia Gerstein, Hertzel Colhoun, Helen Martina Dagenais, Gilles R. Diaz, Rafael Dyal, Leanne Lakshmanan, Mark Mellbin, Linda Probstfield, Jeffrey Riddle, Matthew Casey Shaw, Jonathan Edward Avezum, Alvaro Basile, Jan Neil Cushman, William C. Jansky, Petr Keltai, Mátyás Lanas, Fernando Leiter, Lawrence Alan Lopez-Jaramillo, Patricio Pais, Prem Pīrāgs, Valdis Pogosova, Nana Raubenheimer, Peter Johann Huey-Herng Sheu, Wayne Rydén, Lars |
| dc.contributor.author.none.fl_str_mv |
Ferrannini, Giulia Gerstein, Hertzel Colhoun, Helen Martina Dagenais, Gilles R. Diaz, Rafael Dyal, Leanne Lakshmanan, Mark Mellbin, Linda Probstfield, Jeffrey Riddle, Matthew Casey Shaw, Jonathan Edward Avezum, Alvaro Basile, Jan Neil Cushman, William C. Jansky, Petr Keltai, Mátyás Lanas, Fernando Leiter, Lawrence Alan Lopez-Jaramillo, Patricio Pais, Prem Pīrāgs, Valdis Pogosova, Nana Raubenheimer, Peter Johann Huey-Herng Sheu, Wayne Rydén, Lars |
| dc.contributor.researchgroup.spa.fl_str_mv |
Masira |
| dc.subject.proposal.eng.fl_str_mv |
Cardiovascular disease GLP-1-based therapy Metformin Mortality Morbidity |
| topic |
Cardiovascular disease GLP-1-based therapy Metformin Mortality Morbidity |
| description |
Digital |
| publishDate |
2021 |
| dc.date.issued.none.fl_str_mv |
2021-07-07 |
| dc.date.accessioned.none.fl_str_mv |
2022-02-21T15:21:53Z |
| dc.date.available.none.fl_str_mv |
2022-02-21T15:21:53Z |
| dc.type.spa.fl_str_mv |
Artículo de revista |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
| dc.type.content.spa.fl_str_mv |
Text |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/ART |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
http://purl.org/coar/resource_type/c_6501 |
| status_str |
publishedVersion |
| dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1093/eurheartj/ehaa777 |
| dc.identifier.uri.none.fl_str_mv |
https://repositorio.udes.edu.co/handle/001/6070 |
| url |
https://doi.org/10.1093/eurheartj/ehaa777 https://repositorio.udes.edu.co/handle/001/6070 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.citationendpage.spa.fl_str_mv |
2573 |
| dc.relation.citationissue.spa.fl_str_mv |
26 |
| dc.relation.citationstartpage.spa.fl_str_mv |
2565 |
| dc.relation.citationvolume.spa.fl_str_mv |
42 |
| dc.relation.cites.none.fl_str_mv |
Giulia Ferrannini, Hertzel Gerstein, Helen Martina Colhoun, Gilles R Dagenais, Rafael Diaz, Leanne Dyal, Mark Lakshmanan, Linda Mellbin, Jeffrey Probstfield, Matthew Casey Riddle, Jonathan Edward Shaw, Alvaro Avezum, Jan Neil Basile, William C Cushman, Petr Jansky, Mátyás Keltai, Fernando Lanas, Lawrence Alan Leiter, Patricio Lopez-Jaramillo, Prem Pais, Valdis Pīrāgs, Nana Pogosova, Peter Johann Raubenheimer, Wayne Huey-Herng Sheu, Lars Rydén, Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin, European Heart Journal, Volume 42, Issue 26, 7 July 2021, Pages 2565–2573, https://doi.org/10.1093/eurheartj/ehaa777 |
| dc.relation.indexed.spa.fl_str_mv |
Scopus |
| dc.relation.ispartofjournal.spa.fl_str_mv |
European Heart Journal |
| dc.rights.spa.fl_str_mv |
Copyright © The Authors, European Society of Cardiology, 2021 |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_14cb |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/closedAccess |
| dc.rights.creativecommons.spa.fl_str_mv |
Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc/4.0/ |
| rights_invalid_str_mv |
Copyright © The Authors, European Society of Cardiology, 2021 Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_14cb |
| eu_rights_str_mv |
closedAccess |
| dc.format.extent.spa.fl_str_mv |
11 p |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
European Society of Cardiology |
| dc.publisher.place.spa.fl_str_mv |
Reino Unido |
| dc.source.spa.fl_str_mv |
https://academic.oup.com/eurheartj/article-abstract/42/26/2565/5983740?redirectedFrom=fulltext |
| institution |
Universidad de Santander |
| bitstream.url.fl_str_mv |
https://repositorio.udes.edu.co/bitstreams/e53eda6b-527d-4f01-b6c3-0e7f4b6c176d/download https://repositorio.udes.edu.co/bitstreams/0dc80630-e273-4f94-b719-d06120174e78/download https://repositorio.udes.edu.co/bitstreams/417d5938-ec1e-4ea3-963f-4d77ae9d2976/download https://repositorio.udes.edu.co/bitstreams/821496af-0ae9-43d4-8f71-35245fea78c9/download |
| bitstream.checksum.fl_str_mv |
7f3cd2e9eadc56023e03f3fcac8c1bbb 38d94cf55aa1bf2dac1a736ac45c881c 5dbe86c1111d64f45ba435df98fdc825 0ed7b7aa53408f6e4e5f71c6ea3eb762 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Universidad de Santander |
| repository.mail.fl_str_mv |
soporte@metabiblioteca.com |
| _version_ |
1814158695134658560 |
| spelling |
Ferrannini, Giulia700f79f0-249c-4143-acbe-9d4e93804284-1Gerstein, Hertzel60e256d7-f51a-4e5d-a62f-f7fbf6d1a127-1Colhoun, Helen Martinad1926df9-f100-4e48-93f7-9416dd645c8c-1Dagenais, Gilles R.f72492d7-dc96-43b0-9237-b00656585504-1Diaz, Rafaelf2be4a74-501a-4e63-8bbd-965cbcf8c57b-1Dyal, Leanne2c1519ed-7131-4c64-ae64-60293a636b7c-1Lakshmanan, Marke4d26b36-1c41-49d9-9c19-d57fb2109f53-1Mellbin, Lindad340a8a0-6d09-4a15-9501-cdae07237a92-1Probstfield, Jeffreycce7af47-ba6b-4280-bbb5-4c0a46da5d7d-1Riddle, Matthew Casey1625e52e-c09a-4b37-81ee-7ba1f23b23d4-1Shaw, Jonathan Edward1b07a9e7-7e01-44eb-aca2-6aca57cf2791-1Avezum, Alvaro8b920360-abb2-4ec8-b5ee-4e3f4e0b11eb-1Basile, Jan Neil36596396-2380-4bb1-8609-0e6a2b136645-1Cushman, William C.6e873915-69b2-4696-afa0-6d21bbeb3531-1Jansky, Petrbf8ec62a-6edc-439c-a698-2e4fa4172f04-1Keltai, Mátyás615804f9-6a5a-4e27-953a-628253ea049f-1Lanas, Fernandod22b7fe4-9f1f-4028-a22b-be782ef03d3c-1Leiter, Lawrence Alan5360e239-163c-404d-abed-06ee989532a2-1Lopez-Jaramillo, Patricio9a71267b-dcb0-4d31-b37d-2d30be58d4d2-1Pais, Prem5abdbf77-3c3f-4396-8634-83723aa215b9-1Pīrāgs, Valdis9d0787a3-2e98-4b53-9c97-31f610df30fe-1Pogosova, Nana0f2fb5e5-6659-4562-96e6-74c03e0c46bf-1Raubenheimer, Peter Johann1d8703b0-35b6-479e-8e0f-d73bbd20b2db-1Huey-Herng Sheu, Wayne1d7e1fec-f627-4276-8d26-fea393b02bc0-1Rydén, Larsfbe7a352-5488-4e8a-866d-b966ed6789b4-1Masira2022-02-21T15:21:53Z2022-02-21T15:21:53Z2021-07-07DigitalObjective Recent European Guidelines for Diabetes, Prediabetes and Cardiovascular Diseases introduced a shift in managing patients with type 2 diabetes at high risk for or established cardiovascular (CV) disease by recommending GLP-1 receptor agonists and SGLT-2 inhibitors as initial glucose-lowering therapy. This is questioned since outcome trials of these drug classes had metformin as background therapy. In this post hoc analysis, the effect of dulaglutide on CV events was investigated according to the baseline metformin therapy by means of a subgroup analysis of the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. Research design and methods Patients in REWIND (n = 9901; women: 46.3%; mean age: 66.2 years) had type 2 diabetes and either a previous CV event (31%) or high CV risk (69%). They were randomized (1:1) to sc. dulaglutide (1.5 mg/weekly) or placebo in addition to standard of care. The primary outcome was the first of a composite of nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular or unknown causes. Key secondary outcomes included a microvascular composite endpoint, all-cause death, and heart failure. The effect of dulaglutide in patients with and without baseline metformin was evaluated by a Cox regression hazard model with baseline metformin, dulaglutide assignment, and their interaction as independent variables. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by a Cox regression model with adjustments for factors differing at baseline between people with vs. without metformin, identified using the backward selection. Results Compared to patients with metformin at baseline (n = 8037; 81%), those without metformin (n = 1864; 19%) were older and slightly less obese and had higher proportions of women, prior CV events, heart failure, and renal disease. The primary outcome occurred in 976 (12%) participants with baseline metformin and in 281 (15%) without. There was no significant difference in the effect of dulaglutide on the primary outcome in patients with vs. without metformin at baseline [HR 0.92 (CI 0.81–1.05) vs. 0.78 (CI 0.61–0.99); interaction P = 0.18]. Findings for key secondary outcomes were similar in patients with and without baseline metformin. Conclusion This analysis suggests that the cardioprotective effect of dulaglutide is unaffected by the baseline use of metformin therapy.Ciencias Médicas y de la Salud11 papplication/pdfhttps://doi.org/10.1093/eurheartj/ehaa777https://repositorio.udes.edu.co/handle/001/6070engEuropean Society of CardiologyReino Unido257326256542Giulia Ferrannini, Hertzel Gerstein, Helen Martina Colhoun, Gilles R Dagenais, Rafael Diaz, Leanne Dyal, Mark Lakshmanan, Linda Mellbin, Jeffrey Probstfield, Matthew Casey Riddle, Jonathan Edward Shaw, Alvaro Avezum, Jan Neil Basile, William C Cushman, Petr Jansky, Mátyás Keltai, Fernando Lanas, Lawrence Alan Leiter, Patricio Lopez-Jaramillo, Prem Pais, Valdis Pīrāgs, Nana Pogosova, Peter Johann Raubenheimer, Wayne Huey-Herng Sheu, Lars Rydén, Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin, European Heart Journal, Volume 42, Issue 26, 7 July 2021, Pages 2565–2573, https://doi.org/10.1093/eurheartj/ehaa777ScopusEuropean Heart JournalCopyright © The Authors, European Society of Cardiology, 2021info:eu-repo/semantics/closedAccessAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_14cbhttps://academic.oup.com/eurheartj/article-abstract/42/26/2565/5983740?redirectedFrom=fulltextCardiovascular diseaseGLP-1-based therapyMetforminMortalityMorbiditySimilar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metforminArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85Todas las AudienciasPublicationORIGINALSimilar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline.pdfSimilar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline.pdfapplication/pdf266388https://repositorio.udes.edu.co/bitstreams/e53eda6b-527d-4f01-b6c3-0e7f4b6c176d/download7f3cd2e9eadc56023e03f3fcac8c1bbbMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-859https://repositorio.udes.edu.co/bitstreams/0dc80630-e273-4f94-b719-d06120174e78/download38d94cf55aa1bf2dac1a736ac45c881cMD52TEXTSimilar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline.pdf.txtSimilar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline.pdf.txtExtracted texttext/plain5https://repositorio.udes.edu.co/bitstreams/417d5938-ec1e-4ea3-963f-4d77ae9d2976/download5dbe86c1111d64f45ba435df98fdc825MD53THUMBNAILSimilar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline.pdf.jpgSimilar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline.pdf.jpgGenerated Thumbnailimage/jpeg6834https://repositorio.udes.edu.co/bitstreams/821496af-0ae9-43d4-8f71-35245fea78c9/download0ed7b7aa53408f6e4e5f71c6ea3eb762MD54001/6070oai:repositorio.udes.edu.co:001/60702023-10-09 18:25:07.686https://creativecommons.org/licenses/by-nc/4.0/Copyright © The Authors, European Society of Cardiology, 2021https://repositorio.udes.edu.coRepositorio Universidad de Santandersoporte@metabiblioteca.comTGljZW5jaWEgZGUgUHVibGljYWNpw7NuIFVERVMKRGlyZWN0cmljZXMgZGUgVVNPIHkgQUNDRVNPCgo= |